About Fourrts (India) Laboratories Private Limited
Data last updated:
Fourrts (India) Laboratories Private Limited is a private limited company based in Chennai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 31 March 1979 and has been in existence for over 47 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U85185TN1979PTC007782. Its GSTIN is 33AAACF0467F1Z3 (Tamil Nadu). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹100 Cr and a paid-up capital of ₹6.29 Cr. It was formerly known as Fourts (India) Laboratories Private Limited. It is led by directors including Sekharipuram Viswanathan Veeramani (Managing Director) and Veerramani Radha.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No.1 & 2 Fourrts Avenue Annai Indira Nagar Okkiyam Thoraipakkam, Chennai, Tamil Nadu, India – 600096.
As per the financials filed for FY 2025, the company reported a revenue of ₹778.3 Cr, a growth of 2% compared to the previous year. For the same year it recorded a net profit of ₹40.21 Cr (net margin 5.2%) and EBITDA of ₹80.94 Cr (EBITDA margin 10.4%). Revenue has grown at a compounded annual rate (CAGR) of 7% over three years and 8% over five years.
The company has about 2,603 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Fourrts Laboratories. As per MCA filings, the company has open charges of ₹381.37 Cr and satisfied charges of ₹107.44 Cr on record. Court records list 19 cases involving the company, including 8 filed by the company and 11 filed against it; 6 cases are pending. The company has 14 deals on record (9 secondary share transfers, 3 funding rounds, 2 rights issues), with disclosed funding of ₹25.21 Cr; the latest was in August 2024. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 5 smaller; the largest is Synokem Pharmaceuticals Limited with revenue of ₹791.15 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website fourrts.com.
Company details
Contact details
Fourrts (India) Laboratories Private Limited's registered office is in Chennai, Tamil Nadu. Its website is fourrts.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No.1 & 2 Fourrts Avenue Annai Indira Nagar Okkiyam Thoraipakkam, Chennai, Tamil Nadu, India – 600096
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Fourrts (India) Laboratories Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Fourrts (India) Laboratories operates one associated brand: Fourrts Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacture and marketing of finished nutraceutical supplements | fourrts.com |
Business activity
The main business activity of Fourrts (India) Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Fourrts (India) Laboratories Private Limited, buy the company report.
Financials of Fourrts (India) Laboratories Private Limited
FY 2025 filings availableFourrts (India) Laboratories Private Limited reported revenue of ₹778.3 Cr (up 2% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 8% over five years, including 2% growth in the latest year. EBITDA rose 82% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹778.3 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹80.94 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹40.21 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 10.4% | ||||
| Net Profit Margin | 5.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Fourrts (India) Laboratories Private Limited, buy the company report.
Board of directors of Fourrts (India) Laboratories Private Limited
Fourrts (India) Laboratories has 6 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sekharipuram Viswanathan Veeramani Also directs: Tindivanam Pharma Park Association | Managing Director | 31 Mar 1979 | 47 Years 7 Months | Current |
| Veerramani Radha | Director | 31 Oct 1991 | 35 Years 0 Months | Current |
| Gayatri Veeramani Jayaraman | Director | 15 Dec 2021 | 4 Years 10 Months | Current |
| Sundar Jayaraman | Director | 15 Dec 2021 | 4 Years 10 Months | Current |
| Mohan Lakshminarayan Iyer | Director | 15 Dec 2021 | 4 Years 10 Months | Current |
| Nitia Mohan | Director | 15 Dec 2021 | 4 Years 10 Months | Current |
Peer comparison
Fourrts (India) Laboratories Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Synokem Pharmaceuticals Limited | ₹791.15 Cr (FY 2025) | 0.0% | New Delhi, Delhi, India | |||
| Prime Pharmaceuticals Private Limited | ₹783.06 Cr (FY 2025) | 131.0% | Mumbai, Maharashtra, India | |||
| Fourrts (India) Laboratories Private Limitedthis company | ₹778.3 Cr (FY 2025) | ₹40.21 Cr | 5.2% | 2.0% | 2,603 | Chennai, Tamil Nadu, India |
| Windlas Biotech Limited | ₹777.9 Cr (FY 2025) | 21.0% | Dehradun, Uttarakhand, India | |||
| Pritam International Private Limited | ₹758.46 Cr (FY 2025) | 15.0% | Kolkata, West Bengal, India | |||
| Indchemie Health Specialities Private Limited | ₹734.44 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Sanofi-Synthelabo (India) Private Limited | ₹729.49 Cr (FY 2020) | 16.0% | Mumbai, Maharashtra, India | |||
| Apotex Research Private Limited | ₹727.34 Cr (FY 2025) | 22.0% | Jigani Hobli, Karnataka, India | |||
| Servier India Private Limited | ₹685.38 Cr (FY 2025) | 35.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Fourrts (India) Laboratories Private Limited, buy the company report.
Auditor
Fourrts (India) Laboratories Private Limited is audited by VIJAYARAGHAVAN & ASSOCIATES for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| VIJAYARAGHAVAN & ASSOCIATES | FY 2024 | 0005699S |
Shareholding
The shareholding of Fourrts (India) Laboratories Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Fourrts (India) Laboratories Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 Oct 2024 | 101046546 | Hdfc Bank Limited | ₹80 Lakh | Open | |
| 19 Aug 2024 | 100993968 | Others | ₹1.73 Cr | Open | |
| 26 Feb 2024 | 100956528 | Others | ₹68.9 Lakh | Open | |
| 30 May 2022 | 100601406 | Bank of India | ₹60 Lakh | Open | |
| 17 Nov 2021 | 100511477 | Axis Bank Limited | ₹17.8 Cr | Open |
To see the full charge records of Fourrts (India) Laboratories Private Limited, buy the company report.
Total charge records: 32 View all charges
Deals & funding
Fourrts (India) Laboratories Private Limited has 14 deals on record (9 secondary share transfers, 3 funding rounds, 2 rights issues), with disclosed funding of ₹25.21 Cr; the latest was in August 2024.
Deals on record (5 of 14)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2024 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Jul 2024 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Jul 2024 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Jul 2024 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Jun 2024 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
To see the full deal history of Fourrts (India) Laboratories Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Fourrts (India) Laboratories Private Limited has 19 court cases on record: 8 filed by Fourrts (India) Laboratories, 11 filed against it. 6 cases are pending and 13 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 10 | 2 | 0 |
| District courts | 6 | 6 | 3 |
| NCLAT | 3 | 3 | 3 |
Cases on record (5 of 19)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLAT, Chairperson Court | Tribunal matter | Filed against the company by Shri Nimish Chudgar MD & Ceo of Intas Pharmaceuticals Limited | Pending |
| Madras High Court | Court case (C.S(COMM DIV)) | Filed by the company against Sakhiya Skin Clinic Limited | Disposed |
| Madras High Court | Appeal | Filed by the company against Sakhiya Skin Clinic Limited | Disposed |
| Madras High Court | Original application | Filed by the company against Sakhiya Skin Clinic Limited | Disposed |
| High Court, TAMIL NADU | Original application | Filed by the company against M/S.Azillian Healthcare Pvt Ltd., and 2 others | Disposed |
To see the full case history of Fourrts (India) Laboratories Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Fourrts (India) Laboratories Private Limited was last rated by Care on 07 Dec 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 07 Dec 2022 |
To see the full credit ratings and regulatory alerts of Fourrts (India) Laboratories Private Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Fourrts (India) Laboratories Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Fourrts (India) Laboratories Private Limited has a workforce of 2,603 employees on its EPFO records as of Mar 07, 2025, across 1 active EPFO establishment.
GST
Fourrts (India) Laboratories has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAACF0467F1Z3 | Tamil Nadu | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Fourrts (India) Laboratories Private Limited, buy the company report.
Recent activity
Fourrts (India) Laboratories Private Limited has 10 board changes on record since 1979: 6 appointments and 4 cessations. The latest: Gayatri Veeramani Jayaraman ceased to be Additional Director on 29 Sep 2022.
53 earlier events are in the company report.
Frequently asked questions
Fourrts (India) Laboratories is an active private limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 31 March 1979 (47+ years old) and is registered under CIN U85185TN1979PTC007782.
Fourrts (India) Laboratories has 6 current directors:
- Sekharipuram Viswanathan Veeramani - Managing Director
- Veerramani Radha - Director
- Gayatri Veeramani Jayaraman - Director
- Sundar Jayaraman - Director
- Mohan Lakshminarayan Iyer - Director
- Nitia Mohan - Director
The latest financial statements of Fourrts (India) Laboratories on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Fourrts (India) Laboratories is 33AAACF0467F1Z3, registered in Tamil Nadu. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Fourrts (India) Laboratories is U85185TN1979PTC007782. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Fourrts (India) Laboratories has 19 court cases on record: 8 filed by the company and 11 filed against it. 6 are pending. Most are in the high courts.
Fourrts (India) Laboratories was incorporated on 31 March 1979, making it 47+ years old. It is registered with the Registrar of Companies, Chennai.
Fourrts (India) Laboratories has 14 deals on record (9 secondary share transfers, 3 funding rounds, 2 rights issues), with disclosed funding of ₹25.21 Cr; the latest was in August 2024.
The peers of Fourrts (India) Laboratories by revenue are Synokem Pharmaceuticals Limited, Prime Pharmaceuticals Private Limited, Windlas Biotech Limited, Pritam International Private Limited, Indchemie Health Specialities Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Gayatri Veeramani Jayaraman ceased to be Additional Director on 29 Sep 2022. Mohan Iyer ceased to be Additional Director on 29 Sep 2022. Nitia Mohan ceased to be Additional Director on 29 Sep 2022. Fourrts (India) Laboratories has 10 board changes on record in total.
Fourrts (India) Laboratories can be reached through the website fourrts.com. Its registered office is in Chennai, Tamil Nadu, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
